← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePreclinical
trastuzumab (Herceptin, Pertuzumab Plus Trastuzumab)
Roche / Genentech·Breast Cancer
30 trials
Overview
Program
Pertuzumab Plus Trastuzumab
Overview
Company
Roche / Genentech
Overview
Modality
ANTIBODY
Overview
Target
Breast Cancer
Overview
Indication
Breast Cancer
Overview
Phase
PRECLINICAL
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.. Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (…
Clinical
Safety signal
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.. Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (…
Clinical
Selected reported efficacy
ORR 69.3%
Clinical
Reported ORR
69.3%
Clinical
Result source
ClinicalTrials.gov NCT01120184
Clinical
Program phase
PRECLINICAL
Clinical
Trial ref
NCT01120184